Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors (Q59273887)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

ChEBI release 2020-05-28

ChEBI ID

83766

phase I clinical trial

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

E Winer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

N M Tung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

S J Isakoff

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

B Graña

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

P D Ryan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

E S Lowe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

P Frewer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

J Baselga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

J E Garber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

14 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

1656-1663

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Synthetic lethality: General principles, utility and detection using genetic screens in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU187

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827126%20AND%20SRC:MED&resulttype=core&format=json